placebo + ketamine

Placebo + ketamine refers to a specific pharmacological intervention arm used in clinical research, notably in a Phase 1 pilot study conducted at Yale University (NCT00106119). This combination serves as a control or baseline model for schizophrenia-like symptoms in healthy volunteers. The protocol involves the oral administration of an inactive placebo followed by an intravenous infusion of ketamine. Ketamine acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which induces transient cognitive deficits, perceptual alterations, and psychotic symptoms that mimic the pathophysiology of schizophrenia. This model is utilized to evaluate the potential of novel antipsychotic agents, such as glycine transporter-1 (GlyT1) inhibitors, to attenuate these induced symptoms compared to the placebo + ketamine baseline.

Brand names

Ketalar

Other names

Placebo and Ketamine